Kazia Annual Report 2022

8 KEY MILESTONES HIGHLIGHTS – 2021/2022 November 2021 Paxalisib commences recruitment to a phase II adaptive study in DIPG run by the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study administers paxalisib with ONC201, a combination which has shown evidence of activity in preclinical data and compassionate use. GBM AGILE pivotal study of paxalisib in glioblastoma expands to Canada. February 2022 A phase II study of paxalisib in combination with a ketogenic diet for the treatment of glioblastoma commences recruitment at Weill Cornell Medicine. This study is informed by world-class research from Professor Lew Cantley, who discovered the PI3K pathway that paxalisib targets. May 2022 GBM AGILE pivotal study of paxalisib in glioblastoma expands to Europe. September 2021 EVT801 is granted approval by ANSM, the French regulatory agency, to commence a phase I clinical trial, less than six months after the asset was licensed by Kazia. November 2021 EVT801 phase I study commences recruitment at Oncopole Hospital in Toulouse, France. The biomarker-enhanced study is intended to provide safety and dosing data but also to demonstrate the pharmacological activity of EVT801. December 2021 Kazia releases top-line final data from phase II study of paxalisib in glioblastoma, showing meaningful signals of efficacy. Kazia expands management team with two senior USbased appointments: Dr John Friend as Chief Medical Officer, and Karen Krumeich as Chief Financial Officer. These appointments bring, in aggregate, more than 50 years of biotech experience to the management team. April 2022 Preclinical data in AT/RT, a rare childhood brain cancer is presented at the AACR conference. This data expands the opportunity for paxalisib in childhood brain cancer, positioning it as a substantial area of focus for the drug’s development.

RkJQdWJsaXNoZXIy MjE2NDg3